Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | TERT | O14746 | 5/20 | 0.67 |
| ▸ | TOP1 | P11387 | 4/20 | 0.56 |
| ▸ | CYCS | P99999 | 3/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL31042928 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL8994427 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL2334465 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL498417 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL5051415 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL23706379 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| Zinc Ion SCHEMBL11569891 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL9267975 | 0.97 | TERT (0.71) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL2334489 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 | |
| SCHEMBL30205815 | 0.97 | ENPP2 (0.70) | ENPP2TERTTOP1CYCSABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-6676928-B2 | AS CONTRAST MEDIA FOR THE VISUALIZATION OF MALIGNANT TUMORS, LYMPH NODES AND NECROTIC TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-6641797-B2 | As contrast media for the visualization of malignant tumors, lymph nodes and necrotic tissue | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | SCHERING AG (DE) | 2002-06-20 | — | — | US | disclosed |
| US-6083479-A | Contrast media for infarction and necrosis imaging | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020076379-A1 | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use | FGB, MSR1, FFAR1 | ENPP2 1719/4885TERT 4595/4885TOP1 1009/4885 |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | ENPP2 3094/4885TERT 4635/4885TOP1 1930/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | ENPP2 3109/4885TERT 4478/4885TOP1 1397/4885 |
| US-20020076380-A1 | Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use | FFAR1, FGB, FCGRT | ENPP2 2262/4885TERT 4049/4885TOP1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.